B2B PHARMA & HOSPITAL

B2B Pharma Brand Credibility & Hospital Formulary Decision Survey

Map how hospital formulary committees, medical affairs leads, and procurement heads evaluate, compare, and choose pharma brands across clinical evidence, pricing, and supply reliability, so you can sharpen positioning, fix conversion gaps, and benchmark credibility by formulary tier.

Pan-India sample
Hospital procurement teams (Formulary Decision-Makers)
15-20 min
Talk to a Survey Consultant
Formulary entry frictionIdentify where pharma brands stall or lose formulary inclusion decisions.
Credibility drivers & tier benchmarksRank clinical, pricing, and supply signals by formulary committee weight.
TRUSTED BY LEADING BRANDS
Brand 0Brand 1Brand 2Brand 3Brand 4Brand 5Brand 6Brand 7Brand 8Brand 9Brand 10Brand 11Brand 12Brand 13Brand 14Brand 15Brand 16Brand 17Brand 18Brand 19Brand 20Brand 21Brand 22Brand 23Brand 24Brand 25Brand 26Brand 27Brand 28Brand 29Brand 30Brand 31

CONTEXT & RELEVANCE

Why run this survey now

Most pharma brand teams don't lose formulary position purely on clinical data. They lose it due to weak medical rep credibility, misaligned KOL messaging, poor pharmacy-level visibility, inconsistent CME engagement, and formulary committee blind spots, none of which fully show up in prescription audit reports or sales force effectiveness trackers.

If you are...

  • Pharma brand vs generic competition
  • Hospital formulary inclusion teams
  • Medical affairs or brand head
  • Hospital sales or KAM lead
  • Institutional business strategy teams

You're likely facing...

  • Formulary rejection: credibility vs efficacy
  • KOL trust gap: brand vs generic
  • Rep visit drop-off: access stage
  • Branded = expensive/rigid perception
  • Switching risk at formulary renewal

This will help answer...

  • Formulary decision drivers ranked
  • Credibility gap by brand tier
  • Hospital segment preference split
  • Pricing tolerance vs brand equity
  • Formulary retention and switch triggers

RESEARCH THEMES

What This Survey Investigates

Eight interconnected research themes that map the complete pharma brand credibility journey from formulary consideration to sustained prescriber advocacy.

TENETS 01

Brand Awareness & Recall

  • Unaided brand recall, therapeutic category
  • Medical rep visit frequency, channel
TENETS 02

Formulary Inclusion Drivers

  • Formulary committee criteria, priority weight
  • Therapeutic equivalence, substitution policy
TENETS 03

Clinical Evidence Trust

  • RCT data credibility, local trial weight
  • Post-marketing surveillance, real-world evidence
TENETS 04

Prescriber Preference Signals

  • Brand switching triggers, loyalty thresholds
  • Generic substitution comfort, innovator bias
TENETS 05

Pricing & Access

  • Price band tolerance, DPCO sensitivity
  • Patient assistance program awareness, uptake
TENETS 06

MSL & Rep Engagement

  • Medical Science Liaison visit quality, depth
  • Detailing content relevance, call frequency
TENETS 07

KOL & Peer Influence

  • KOL endorsement weight, specialty society signals
  • Peer-to-peer referral patterns, CME influence
TENETS 08

Competitive Positioning

  • Head-to-head brand comparison, category rank
  • Unmet need gaps, switching intent signals

SAMPLING STRATEGY

Tell us about your ideal sample

Help us understand your target respondent profile. Select what applies, we'll design the optimal sample plan based on your inputs.

Sample size
How many respondents do you need?
Not Selected
Target audience
Who should we survey?
Not Selected
Region
Which regions should we cover?
Not Selected
Segments
How should we slice the data?
Not Selected
Discuss sample plan

METHODOLOGY

Survey approach

For the B2B Pharma Brand Credibility and Hospital Formulary Decision Survey, we recommend a quant-first design with flexible data-collection modes to balance reach, depth, and verification across hospital and formulary committee respondents.

PRIMARY
Online web surveySelf-administered survey shared via email / panels to capture structured responses at scale.
Best for
1
Ranking pharma brand credibility drivers by specialty.
2
Measuring formulary inclusion criteria across hospital tiers.
3
Comparing prescriber segments by institution type and region.
Deliverables
Credibility driver ranking
Formulary gap matrix
Segment comparison cuts
OPTIONAL
CATI (phone survey)Interviewer-led telephone interviews to reach owners who are harder to get online.
Best for
1
Senior formulary committee members with low digital access.
2
Rapid coverage across Tier 2 and Tier 3 hospital clusters.
Deliverables
Committee coverage data
Call-log diagnostics
SELECTIVE
Face-to-faceOn-ground surveys or interviews in key industrial clusters or high-value cohorts.
Best for
1
Key opinion leaders and formulary chairs at flagship hospitals.
2
High-influence procurement heads requiring in-person verification.
Deliverables
KOL influence maps
Formulary decision narratives
OPTIONAL
FGDs
Deliverables
Themes and verbatims
Messaging concept feedback
OPTIONAL
Mixed surveysAny 4-mode combo Online + CATI + F2F + FGDs to maximise reach and representation. Mode-specific quotas and weighting for clean comparisons.
Deliverables
Unified dataset
Mode-adjusted analytics
Our Recommendation
Start with: Online web survey as the core quantitative layer, targeting hospital pharmacists, formulary committee members, and specialist prescribers across public and private hospital tiers.
Consider adding: CATI for senior formulary chairs in Tier 2 and Tier 3 hospitals with low digital access, and F2F interviews with key opinion leaders at flagship institutions where brand credibility decisions carry the highest commercial weight.

EXECUTION PROCESS

How we execute

A proven 9-step process from scoping to delivery, designed to ensure quality, speed, and actionable insights.

Define the decision frame

Confirm objectives, target cohorts, geographies, and reporting cuts

Step 01

Define the decision frame

Design the instrument

Build workstream modules mapped to outputs (drivers, friction, pricing, retention, trust)

Step 02

Design the instrument

Lock the questionnaire

Review wording, sequencing, LOI, and competitive context; approve final version

Step 03

Lock the questionnaire

Pilot and calibrate

Test comprehension and ease quality; refine quotas and remove friction where needed

Step 04

Pilot and calibrate

Run fieldwork

Execute collection with active quota management and feasibility controls

Step 05

Run fieldwork

Assure quality

Dedupe, attention checks, speed/consistency rules, removals with audit trail

Step 06

Assure quality

Prepare the dataset

Clean data and deliver codebook/variable definitions

Step 07

Prepare the dataset

Analyse and synthesise

Driver ranking, leakage diagnostics, pricing bands, segment insights

Step 08

Analyse and synthesise

Deliver and align

Executive deck (optional dashboard) and leadership readout with recommendations

Step 09

Deliver and align

COMMERCIAL TERMS

Request a Commercial Proposal

Pricing depends on cohort, geography, sample size, approach, LOI, and deliverables. Configure below for an indicative estimate.

Select Sample Size

100

Geography

  • India
  • APAC (Singapore, Vietnam, Philippines, Indonesia, Australia, NZ, Japan, Thailand)
  • Middle East (UAE, KSA, Qatar, Bahrain, Oman, Kuwait)
  • North America (US, Canada)
  • Europe
  • Africa (South Africa, Kenya, Nigeria, Egypt, Algeria)
  • LATAM (Brazil, Mexico)

Select Mode of Survey

  • Online
  • CATI
  • Online FGD (5 people per FGD)
  • F2F

Length of the Interview

  • Select
  • 0-15
  • 16-20
  • 21-30
  • 31-45
  • 46-60
  • Custom
Indicative Estimate
  • Indian Rupee (INR)
  • United Arab Emirates Dirham (AED)
  • Afghan Afghani (AFN)
  • Albanian Lek (ALL)
  • Armenian Dram (AMD)
  • Netherlands Antillean Guilder (ANG)
  • Angolan Kwanza (AOA)
  • Argentine Peso (ARS)
  • Australian Dollar (AUD)
  • Aruban Florin (AWG)
  • Azerbaijani Manat (AZN)
  • Bosnia-Herzegovina Convertible Mark (BAM)
  • Barbadian Dollar (BBD)
  • Bangladeshi Taka (BDT)
  • Bulgarian Lev (BGN)
  • Bahraini Dinar (BHD)
  • Burundian Franc (BIF)
  • Bermudian Dollar (BMD)
  • Brunei Dollar (BND)
  • Bolivian Boliviano (BOB)
  • Brazilian Real (BRL)
  • Bahamian Dollar (BSD)
  • Bhutanese Ngultrum (BTN)
  • Botswana Pula (BWP)
  • Belarusian Ruble (BYN)
  • Belize Dollar (BZD)
  • Canadian Dollar (CAD)
  • Congolese Franc (CDF)
  • Swiss Franc (CHF)
  • Chilean Peso (CLP)
  • Chinese Yuan (CNY)
  • Colombian Peso (COP)
  • Costa Rican Colón (CRC)
  • Cuban Peso (CUP)
  • Cape Verdean Escudo (CVE)
  • Czech Koruna (CZK)
  • Djiboutian Franc (DJF)
  • Danish Krone (DKK)
  • Dominican Peso (DOP)
  • Algerian Dinar (DZD)
  • Egyptian Pound (EGP)
  • Eritrean Nakfa (ERN)
  • Ethiopian Birr (ETB)
  • Euro (EUR)
  • Fijian Dollar (FJD)
  • Falkland Islands Pound (FKP)
  • British Pound (GBP)
  • Georgian Lari (GEL)
  • Ghanaian Cedi (GHS)
  • Gibraltar Pound (GIP)
  • Gambian Dalasi (GMD)
  • Guinean Franc (GNF)
  • Guatemalan Quetzal (GTQ)
  • Guyanese Dollar (GYD)
  • Hong Kong Dollar (HKD)
  • Honduran Lempira (HNL)
  • Croatian Kuna (HRK)
  • Haitian Gourde (HTG)
  • Hungarian Forint (HUF)
  • Indonesian Rupiah (IDR)
  • Israeli New Shekel (ILS)
  • Iraqi Dinar (IQD)
  • Iranian Rial (IRR)
  • Icelandic Króna (ISK)
  • Jamaican Dollar (JMD)
  • Jordanian Dinar (JOD)
  • Japanese Yen (JPY)
  • Kenyan Shilling (KES)
  • Kyrgyzstani Som (KGS)
  • Cambodian Riel (KHR)
  • Comorian Franc (KMF)
  • South Korean Won (KRW)
  • Kuwaiti Dinar (KWD)
  • Cayman Islands Dollar (KYD)
  • Kazakhstani Tenge (KZT)
  • Lao Kip (LAK)
  • Lebanese Pound (LBP)
  • Sri Lankan Rupee (LKR)
  • Liberian Dollar (LRD)
  • Lesotho Loti (LSL)
  • Libyan Dinar (LYD)
  • Moroccan Dirham (MAD)
  • Moldovan Leu (MDL)
  • Malagasy Ariary (MGA)
  • Macedonian Denar (MKD)
  • Burmese Kyat (MMK)
  • Mongolian Tögrög (MNT)
  • Macanese Pataca (MOP)
  • Mauritian Rupee (MUR)
  • Maldivian Rufiyaa (MVR)
  • Malawian Kwacha (MWK)
  • Mexican Peso (MXN)
  • Malaysian Ringgit (MYR)
  • Mozambican Metical (MZN)
  • Namibian Dollar (NAD)
  • Nigerian Naira (NGN)
  • Nicaraguan Córdoba (NIO)
  • Norwegian Krone (NOK)
  • Nepalese Rupee (NPR)
  • New Zealand Dollar (NZD)
  • Omani Rial (OMR)
  • Panamanian Balboa (PAB)
  • Peruvian Sol (PEN)
  • Papua New Guinean Kina (PGK)
  • Philippine Peso (PHP)
  • Pakistani Rupee (PKR)
  • Polish Złoty (PLN)
  • Paraguayan Guaraní (PYG)
  • Qatari Riyal (QAR)
  • Romanian Leu (RON)
  • Serbian Dinar (RSD)
  • Russian Ruble (RUB)
  • Rwandan Franc (RWF)
  • Saudi Riyal (SAR)
  • Solomon Islands Dollar (SBD)
  • Seychellois Rupee (SCR)
  • Sudanese Pound (SDG)
  • Swedish Krona (SEK)
  • Singapore Dollar (SGD)
  • Saint Helena Pound (SHP)
  • Sierra Leonean Leone (SLL)
  • Somali Shilling (SOS)
  • Surinamese Dollar (SRD)
  • São Tomé and Príncipe Dobra (STD)
  • Syrian Pound (SYP)
  • Swazi Lilangeni (SZL)
  • Thai Baht (THB)
  • Tajikistani Somoni (TJS)
  • Turkmenistani Manat (TMT)
  • Tunisian Dinar (TND)
  • Tongan Paʻanga (TOP)
  • Turkish Lira (TRY)
  • Trinidad and Tobago Dollar (TTD)
  • New Taiwan Dollar (TWD)
  • Tanzanian Shilling (TZS)
  • Ukrainian Hryvnia (UAH)
  • Ugandan Shilling (UGX)
  • United States Dollar (USD)
  • Uruguayan Peso (UYU)
  • Uzbekistani Som (UZS)
  • Vietnamese Đồng (VND)
  • Vanuatu Vatu (VUV)
  • Samoan Tālā (WST)
  • Central African CFA Franc (XAF)
  • East Caribbean Dollar (XCD)
  • West African CFA franc (XOF)
  • CFP Franc (XPF)
  • Yemeni Rial (YER)
  • South African Rand (ZAR)
  • Zambian Kwacha (ZMW)
  • Zimbabwean Dollar (ZWL)

$0.00

+ applicable taxes

Proposal turnaround typically 24–48 hours

Note: Estimate is indicative only. Final pricing is subject to scope finalization after discovery call.

REFERENCE CASELETS

Reference

Real-world examples of survey work in the pharma brand and hospital procurement space.

CASELET 1

Physician message recall & prescribing preference mapping (India)

CASELET 2

Hospital formulary inclusion criteria & procurement friction audit (India)

Physician message recall & prescribing preference mapping (India)

OBJECTIVE

A specialty pharma brand needed to identify which message territories drove prescribing preference among consultant physicians and general practitioners , and how medical representative visit frequency shaped brand recall across therapeutic categories.

WHAT WE DID

Ran a structured quant survey across 280 physicians in 6 metros, capturing brand recall rank, message attribution, detailing frequency, sample usage behaviour, and stated preference drivers by prescriber tier and specialty segment.

DELIVERED

A prescriber preference map by specialty, a ranked message territory framework showing which claims drove recall versus which drove intent, and a detailing frequency corridor by physician tier and city cluster.
CASELET 1

Physician message recall & prescribing preference mapping (India)

CASELET 2

Hospital formulary inclusion criteria & procurement friction audit (India)

Physician message recall & prescribing preference mapping (India)

OBJECTIVE

A specialty pharma brand needed to identify which message territories drove prescribing preference among consultant physicians and general practitioners , and how medical representative visit frequency shaped brand recall across therapeutic categories.

WHAT WE DID

Ran a structured quant survey across 280 physicians in 6 metros, capturing brand recall rank, message attribution, detailing frequency, sample usage behaviour, and stated preference drivers by prescriber tier and specialty segment.

DELIVERED

A prescriber preference map by specialty, a ranked message territory framework showing which claims drove recall versus which drove intent, and a detailing frequency corridor by physician tier and city cluster.

FREQUENTLY ASKED QUESTIONS

Common Questions

Answers to frequently asked questions about this survey mandate.

What decisions will this survey enable?

Who is the buyer vs who are the respondents?

Can we see differences between primary care hospitals, specialty tertiary centers and teaching institutions?

How will you measure formulary inclusion preference beyond simple ratings?

Will the survey map the full formulary evaluation journey and drop-offs?

Can this survey inform product and pricing strategy?

How will findings improve our hospital key account and medical affairs performance?

Still have questions?

Schedule a discovery call to discuss your specific needs and get a custom quote.

Book a Discovery Call